de Jesús Ascencio-Montiel: A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19 [Ivermectin]

A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19

de Jesús Ascencio-Montiel et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002

de Jesús Ascencio-Montiel et al., A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19, Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002

Jan 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 28,048 COVID+ patients in Mexico, 7,898 receiving a treatment kit including low dose ivermectin, AZ, aspirin, and acetaminophen, shower lower mortality/hospitalization for those receiving the kit. Delivery of the treatment kit was based on availability in the medical units. Adherence is unknown and may be low. Adjusted results are only provided for combined mortality/hospitalization.

Important missing comments or errors? Let us know.

risk of death/hospitalization, 59.0% lower, RR 0.41, p < 0.001, treatment 7,898, control 20,150, adjusted per study, multivariable, primary outcome.

risk of death/hospitalization, 71.0% lower, RR 0.29, p < 0.001, treatment 5,557, control 12,526, adjusted per study, with phone call followup, multivariable.

risk of death, 15.0% lower, RR 0.85, p = 0.16, treatment 101 of 7,898 (1.3%), control 303 of 20,150 (1.5%), NNT 445, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

risk of mechanical ventilation, 9.1% lower, RR 0.91, p = 0.51, treatment 77 of 7,898 (1.0%), control 216 of 20,150 (1.1%), NNT 1031, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

risk of hospitalization, 47.6% lower, RR 0.52, p < 0.001, treatment 485 of 7,898 (6.1%), control 2,360 of 20,150 (11.7%), NNT 18, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

risk of progression, 41.8% lower, RR 0.58, p < 0.001, treatment 435 of 7,898 (5.5%), control 1,906 of 20,150 (9.5%), NNT 25, unadjusted, ER, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

de Jesús Ascencio-Montiel et al., 24 Jan 2022, retrospective, Mexico, peer-reviewed, 10 authors, dosage 6mg days 1-2, this trial uses multiple treatments in the treatment arm (combined with AZ, acetaminophen, aspirin) - results of individual treatments may vary.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Abstract: Journal Pre-proof A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19 Iván de Jesús Ascencio-Montiel , Juan Carlos Tomás-López , Verónica Álvarez-Medina , Luisa Estela Gil-Velázquez , Hortensia Vega-Vega , Héctor Raúl Vargas-Sánchez , Manuel Cervantes-Ocampo , Miguel Ángel Villası́s-Keever , Cesar Raúl González-Bonilla , Célida Duque-Molina PII: DOI: Reference: S0188-4409(22)00002-9 https://doi.org/10.1016/j.arcmed.2022.01.002 ARCMED 2717 To appear in: Archives of Medical Research Received date: Revised date: Accepted date: August 26, 2021 January 3, 2022 January 13, 2022 Please cite this article as: Iván de Jesús Ascencio-Montiel , Juan Carlos Tomás-López , Verónica Álvarez-Medina , Luisa Estela Gil-Velázquez , Hortensia Vega-Vega , Héctor Raúl Vargas-Sánchez , Manuel Cervantes-Ocampo , Miguel Ángel Villası́s-Keever , Cesar Raúl González-Bonilla , Célida Duque-Molina , A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19, Archives of Medical Research (2022), doi: https://doi.org/10.1016/j.arcmed.2022.01.002 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS). Arch Med Res 21-01098 Archives of Medical Research 53 (2022) x–x ORIGINAL ARTICLE A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19 Iván de Jesús Ascencio-Montiel,a Juan Carlos Tomás-López,b Verónica Álvarez-Medina,b Luisa Estela Gil-Velázquez,b Hortensia VegaVega,b Héctor Raúl Vargas-Sánchez,b Manuel Cervantes-Ocampo,c Miguel Ángel Villasís-Keever,d Cesar Raúl González-Bonilla,d and Célida Duque-Molinaf a Coordinación de Vigilancia Epidemiológica, Unidad de Planeación e Innovación en Salud, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México b División de Medicina Familiar, Coordinación de Unidades de Primer Nivel, Unidad de Atención Médica, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México c Coordinación de Unidades de Primer Nivel, Unidad de Atención Médica, Dirección de Prestaciones Médicas Instituto Mexicano del Seguro Social, Ciudad de México, México d Unidad de Investigación en Análisis y Síntesis de la Evidencia, Coordinación de Investigación en Salud, Unidad de Educación e 1 Arch Med Res 21-01098 Investigación, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México e Coordinación de Investigación en Salud, Unidad de Educación e Investigación, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México f Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México Received for publication August 28, 2021; accepted January 13, 2022..

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit